X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.02 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 160.00K shares, a 678.21% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.86M shares, a 30474.26% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 12.76M shares, a 581.65% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 12.79M shares, a 84.84% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.92M shares.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 4.22M shares, a 986.88% increase from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 388.05K shares, a 55.12% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 160.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 4.02M shares 10-Q · filed 2026-08-06 | 4.02M shares derived: sum of 3 quarters · filed 2026-08-06 | 16.78M shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | 3.86M shares 10-Q · filed 2026-05-06 | 3.86M shares derived: sum of 2 quarters · filed 2026-05-06 | 16.62M shares derived: sum of 3 quarters · filed 2026-05-06 | 16.64M shares derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 12.76M shares derived: sum of 2 quarters · filed 2026-03-17 | 12.78M shares derived: sum of 3 quarters · filed 2026-03-17 | 12.79M shares 10-K · filed 2026-03-17 | |
| 2025-09-30 | 12.76M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 12.78M shares derived: sum of 2 quarters · filed 2025-11-05 | 12.79M shares 10-Q · filed 2025-11-05 | 13.47M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 20.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | 33.19K shares 10-Q · filed 2025-08-08 | 708.36K shares derived: sum of 3 quarters · filed 2025-08-08 | 2.58M shares derived: sum of 4 quarters · filed 2025-08-08 | |
| 2025-03-31 | 12.63K shares 10-Q · filed 2025-05-01 | 687.80K shares derived: sum of 2 quarters · filed 2025-05-01 | 2.56M shares derived: sum of 3 quarters · filed 2025-05-01 | 4.55M shares derived: sum of 4 quarters · filed 2025-05-01 | |
| 2024-12-31 | 675.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 2.55M shares derived: sum of 2 quarters · filed 2025-03-26 | 4.53M shares derived: sum of 3 quarters · filed 2025-03-26 | 6.92M shares 10-K · filed 2025-03-26 | |
| 2024-09-30 | 1.87M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 3.86M shares derived: sum of 2 quarters · filed 2024-11-13 | 6.25M shares 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | 1.99M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 4.37M shares 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 2.39M shares 10-Q · filed 2024-05-07 | ||||
| 2023-09-30 | 2.05M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.81M shares derived: sum of 2 quarters · filed 2023-11-09 | 3.65M shares 10-Q · filed 2023-11-09 | 7.53M shares derived: sum of 4 quarters · filed 2024-03-21 | |
| 2023-06-30 | 762.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.60M shares 10-Q · filed 2023-08-10 | 5.48M shares derived: sum of 3 quarters · filed 2024-03-21 | 5.54M shares derived: sum of 4 quarters · filed 2024-03-21 | |
| 2023-03-31 | 834.90K shares 10-Q · filed 2023-05-04 | 4.71M shares derived: sum of 2 quarters · filed 2024-03-21 | 4.78M shares derived: sum of 3 quarters · filed 2024-03-21 | 4.82M shares derived: sum of 4 quarters · filed 2024-03-21 | |
| 2022-12-31 | 3.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 3.94M shares derived: sum of 2 quarters · filed 2024-03-21 | 3.98M shares derived: sum of 3 quarters · filed 2024-03-21 | 4.22M shares 10-K · filed 2024-03-21 | 759.20K shares 10-K · filed 2023-03-21 |
| 2022-09-30 | 65.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 107.10K shares derived: sum of 2 quarters · filed 2022-11-03 | 339.95K shares 10-Q · filed 2022-11-03 | 391.25K shares derived: sum of 4 quarters · filed 2022-11-03 | |
| 2022-06-30 | 42.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 274.85K shares 10-Q · filed 2022-08-04 | 326.15K shares derived: sum of 3 quarters · filed 2022-08-04 | 486.32K shares derived: sum of 4 quarters · filed 2022-08-04 | |
| 2022-03-31 | 232.85K shares 10-Q · filed 2022-05-12 | 284.15K shares derived: sum of 2 quarters · filed 2022-05-12 | 444.32K shares derived: sum of 3 quarters · filed 2022-05-12 | 523.92K shares derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-12-31 | 51.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 211.47K shares derived: sum of 2 quarters · filed 2022-03-17 | 291.07K shares derived: sum of 3 quarters · filed 2022-03-17 | 388.05K shares 10-K · filed 2022-03-17 | |
| 2021-09-30 | 160.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 239.78K shares derived: sum of 2 quarters · filed 2021-11-04 | 336.75K shares 10-Q · filed 2021-11-04 | 702.70K shares derived: sum of 4 quarters · filed 2021-11-04 | |
| 2021-06-30 | 79.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 176.57K shares 10-Q · filed 2021-08-03 | 542.53K shares derived: sum of 3 quarters · filed 2021-08-03 | 663.95K shares derived: sum of 4 quarters · filed 2021-08-03 | |
| 2021-03-31 | 96.97K shares 10-Q · filed 2021-05-06 | 462.93K shares derived: sum of 2 quarters · filed 2021-05-06 | 584.35K shares derived: sum of 3 quarters · filed 2021-05-06 | 754.82K shares derived: sum of 4 quarters · filed 2021-05-06 | |
| 2020-12-31 | 365.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 487.38K shares derived: sum of 2 quarters · filed 2021-03-19 | 657.84K shares derived: sum of 3 quarters · filed 2021-03-19 | 864.62K shares 10-K · filed 2021-03-19 | |
| 2020-09-30 | 121.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 291.89K shares derived: sum of 2 quarters · filed 2020-11-05 | 498.66K shares 10-Q · filed 2020-11-05 | 606.11K shares derived: sum of 4 quarters · filed 2020-11-05 | |
| 2020-06-30 | 170.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | 377.24K shares 10-Q · filed 2020-08-04 | 484.69K shares derived: sum of 3 quarters · filed 2020-08-04 | 588.44K shares derived: sum of 4 quarters · filed 2020-08-04 | |
| 2020-03-31 | 206.78K shares 10-Q · filed 2020-05-07 | 314.23K shares derived: sum of 2 quarters · filed 2020-05-07 | 417.98K shares derived: sum of 3 quarters · filed 2020-05-07 | 658.97K shares derived: sum of 4 quarters · filed 2020-05-07 | |
| 2019-12-31 | 107.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 211.20K shares derived: sum of 2 quarters · filed 2020-03-12 | 452.20K shares derived: sum of 3 quarters · filed 2020-03-12 | 589.11K shares 10-K · filed 2020-03-12 | |
| 2019-09-30 | 103.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 344.75K shares derived: sum of 2 quarters · filed 2019-11-07 | 481.66K shares 10-Q · filed 2019-11-07 | 481.66K shares derived: sum of 4 quarters · filed 2019-11-07 | |
| 2019-06-30 | 240.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 377.91K shares 10-Q · filed 2019-08-07 | 377.91K shares derived: sum of 3 quarters · filed 2019-08-07 | 377.91K shares derived: sum of 4 quarters · filed 2019-08-07 | |
| 2019-03-31 | 136.91K shares 10-Q · filed 2019-05-15 | 136.91K shares derived: sum of 2 quarters · filed 2019-05-15 | 136.91K shares derived: sum of 3 quarters · filed 2019-05-15 | 263.41K shares derived: sum of 4 quarters · filed 2019-05-15 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | 0.00 shares derived: sum of 2 quarters · filed 2019-03-11 | 126.50K shares derived: sum of 3 quarters · filed 2019-03-11 | 829.50K shares 10-K · filed 2019-03-11 | |
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-09 | 126.50K shares derived: sum of 2 quarters · filed 2018-11-09 | 829.50K shares 10-Q · filed 2018-11-09 | ||
| 2018-06-30 | 126.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | 829.50K shares 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | 703.00K shares 10-Q · filed 2018-05-10 | ||||
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |